The weight loss drugs landscape in the UK underwent a seismic shift on 6 July 2026 when Wegovy – an injectable semaglutide – ...
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist and the active ingredient in the medications Wegovy and ...
Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeksMean weight loss with semaglutide 7.2 mg reached 21%, reflecting overall treatment efficacyUp to 84 ...
New research shows people with type 2 diabetes and chronic kidney disease who took semaglutide (commonly sold as Ozempic) once a week had improved kidney outcomes, even if they had heart disease or a ...
Morning Overview on MSN
A GLP-1 weight-loss drug may slow the body’s biological aging, a new study suggests
Semaglutide, the active ingredient in widely prescribed GLP-1 drugs such as Ozempic and Wegovy, slowed markers of biological ...
Terrestrial Bio has dosed the first patients in a Phase I clinical trial evaluating its patch that delivers GLP-1 therapeutic ...
Indian pharma majors Sun Pharma, Dr Reddy's and Glenmark on Saturday announced the launch of their generic versions of ...
Everyday Health on MSN
Can GLP-1 drugs for obesity and diabetes also treat other diseases?
Researchers are exploring drugs like Ozempic, Mounjaro, and Wegovy to treat or prevent a range of conditions, including ...
A US study suggests GLP-1 drugs like semaglutide may slow biological aging in people with HIV by improving inflammation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results